Baillie Gifford & Co
CRL icon

Baillie Gifford & Co’s Charles River Laboratories CRL Stock Holding History

Baillie Gifford & Co’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49
Closed -$7.38K – 268
2025
Q1 		$7.38K Sell
49
-75,362
-100% -$12.6M ﹤0.01% 261
2024
Q4 		$13.9M Buy
75,411
+6,826
+10% +$1.31M 0.01% 198
2024
Q3 		$13.5M Buy
68,585
+1,048
+2% +$218K 0.01% 200
2024
Q2 		$14M Buy
67,537
+3
+0% +$680 0.01% 197
2024
Q1 		$18.3M Sell
67,534
-2,668
-4% -$637K 0.01% 193
2023
Q4 		$16.6M Sell
70,202
-9,370
-12% -$1.84M 0.01% 202
2023
Q3 		$15.6M Sell
79,572
-5,524
-6% -$1.13M 0.01% 196
2023
Q2 		$17.9M Sell
85,096
-394
-0.5% -$78.4K 0.02% 185
2023
Q1 		$17.3M Buy
85,490
+14,118
+20% +$3.2M 0.02% 191
2022
Q4 		$15.6M Sell
71,372
-527
-0.7% -$115K 0.02% 196
2022
Q3 		$14.2M Buy
71,899
+56,103
+355% +$12.1M 0.01% 201
2022
Q2 		$3.38M Buy
+15,796
New +$3.86M ﹤0.01% 256

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Baillie Gifford & Co's CRL Position: Q2 2025 in Review

Baillie Gifford & Co sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 49 shares — an estimated $7.38K sold.

Baillie Gifford & Co first reported a position in CRL in Q2 2022 and held it in 12 quarters. The position peaked at $18.3M in Q1 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Baillie Gifford & Co reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Baillie Gifford & Co sold 49 Charles River Laboratories shares in Q2 2025, an estimated $7.38K.
  • Baillie Gifford & Co first reported a position in Charles River Laboratories in Q2 2022 and held it in 12 quarters.
  • Baillie Gifford & Co's Charles River Laboratories position peaked at $18.3M in Q1 2024.
  • 519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Baillie Gifford & Co's 13F filing for Q2 2025, filed 6 Aug 2025.